Over the past 20 years, Dr Lynch's lab group has developed an emerging research portfolio for understanding, treating, and eventually curing the rare disease Friedreich Ataxia. Beginning with clinical research studies, this now includes translational studies, biomarker studies, and now basic sciences studies in cells and mouse models.